Jacqueline Shea
Chief Executive Officer at INOVIO PHARMACEUTICALS, INC.
Net worth: 284 707 $ as of 2024-03-30
Profile
Jacqueline E.
Shea is currently the President, Chief Executive Officer & Director at Inovio Pharmaceuticals, Inc. and a Trustee at Albert B.
Sabin Vaccine Institute, Inc. Previously, she served as the Chief Executive Officer at Aeras Global TB Vaccine Foundation from 2015 to 2018.
Prior to that, she was the Vice President-Europe Business Development at Emergent BioSolutions, Inc. from 2013 to 2014 and the Vice President & General Manager at The Oxford-Emergent Tuberculosis Consortium Ltd.
from 2008 to 2013.
Dr. Shea completed her undergraduate degree at the University of Bath and holds a doctorate from The National Institute For Medical Research.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-27 | 20,512 ( 0.09% ) | 284 707 $ | 2024-03-30 |
Jacqueline Shea active positions
| Companies | Position | Start |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Chief Executive Officer | 2022-05-09 |
Albert B. Sabin Vaccine Institute, Inc.
 Albert B. Sabin Vaccine Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Albert B. Sabin Vaccine Institute, Inc. creates solutions to health threats. It works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the pervasive health care challenges. The company was founded in 1993 and is headquartered in Washington, DC. | Director/Board Member | 2019-08-12 |
Former positions of Jacqueline Shea
| Companies | Position | End |
|---|---|---|
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Chief Executive Officer | 2018-11-30 |
| EMERGENT BIOSOLUTIONS INC. | Corporate Officer/Principal | 2014-02-28 |
| The Oxford-Emergent Tuberculosis Consortium Ltd. | Corporate Officer/Principal | 2012-12-31 |
Training of Jacqueline Shea
| University of Bath | Undergraduate Degree |
| The National Institute For Medical Research | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Private companies | 3 |
|---|---|
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
Albert B. Sabin Vaccine Institute, Inc.
Albert B. Sabin Vaccine Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Albert B. Sabin Vaccine Institute, Inc. creates solutions to health threats. It works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the pervasive health care challenges. The company was founded in 1993 and is headquartered in Washington, DC. | Commercial Services |
| The Oxford-Emergent Tuberculosis Consortium Ltd. |
- Stock Market
- Insiders
- Jacqueline Shea
